Global Tumor Radioimmunotherapy Market Research Report 2026

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Radioimmunotherapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Beta-emitting
1.2.3 Targeted Alpha Therapy
1.3 Market by Application
1.3.1 Global Tumor Radioimmunotherapy Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Solid Tumor
1.3.3 Non Hodgkin Lymphoma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor Radioimmunotherapy Market Perspective (2021–2032)
2.2 Global Tumor Radioimmunotherapy Growth Trends by Region
2.2.1 Global Tumor Radioimmunotherapy Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Tumor Radioimmunotherapy Historic Market Size by Region (2021–2026)
2.2.3 Tumor Radioimmunotherapy Forecasted Market Size by Region (2027–2032)
2.3 Tumor Radioimmunotherapy Market Dynamics
2.3.1 Tumor Radioimmunotherapy Industry Trends
2.3.2 Tumor Radioimmunotherapy Market Drivers
2.3.3 Tumor Radioimmunotherapy Market Challenges
2.3.4 Tumor Radioimmunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Radioimmunotherapy Players by Revenue
3.1.1 Global Top Tumor Radioimmunotherapy Players by Revenue (2021–2026)
3.1.2 Global Tumor Radioimmunotherapy Revenue Market Share by Players (2021–2026)
3.2 Global Top Tumor Radioimmunotherapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Tumor Radioimmunotherapy Revenue
3.4 Global Tumor Radioimmunotherapy Market Concentration Ratio
3.4.1 Global Tumor Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Radioimmunotherapy Revenue in 2025
3.5 Global Key Players of Tumor Radioimmunotherapy Head Offices and Areas Served
3.6 Global Key Players of Tumor Radioimmunotherapy, Products and Applications
3.7 Global Key Players of Tumor Radioimmunotherapy, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Tumor Radioimmunotherapy Breakdown Data by Type
4.1 Global Tumor Radioimmunotherapy Historic Market Size by Type (2021–2026)
4.2 Global Tumor Radioimmunotherapy Forecasted Market Size by Type (2027–2032)
5 Tumor Radioimmunotherapy Breakdown Data by Application
5.1 Global Tumor Radioimmunotherapy Historic Market Size by Application (2021–2026)
5.2 Global Tumor Radioimmunotherapy Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Tumor Radioimmunotherapy Market Size (2021–2032)
6.2 North America Tumor Radioimmunotherapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Tumor Radioimmunotherapy Market Size by Country (2021–2026)
6.4 North America Tumor Radioimmunotherapy Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor Radioimmunotherapy Market Size (2021–2032)
7.2 Europe Tumor Radioimmunotherapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Tumor Radioimmunotherapy Market Size by Country (2021–2026)
7.4 Europe Tumor Radioimmunotherapy Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Tumor Radioimmunotherapy Market Size (2021–2032)
8.2 Asia-Pacific Tumor Radioimmunotherapy Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Tumor Radioimmunotherapy Market Size by Region (2021–2026)
8.4 Asia-Pacific Tumor Radioimmunotherapy Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Tumor Radioimmunotherapy Market Size (2021–2032)
9.2 Latin America Tumor Radioimmunotherapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Tumor Radioimmunotherapy Market Size by Country (2021–2026)
9.4 Latin America Tumor Radioimmunotherapy Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Radioimmunotherapy Market Size (2021–2032)
10.2 Middle East & Africa Tumor Radioimmunotherapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Tumor Radioimmunotherapy Market Size by Country (2021–2026)
10.4 Middle East & Africa Tumor Radioimmunotherapy Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Tumor Radioimmunotherapy Introduction
11.1.4 Bayer Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.1.5 Bayer Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Tumor Radioimmunotherapy Introduction
11.2.4 Novartis Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.2.5 Novartis Recent Development
11.3 Lantheus
11.3.1 Lantheus Company Details
11.3.2 Lantheus Business Overview
11.3.3 Lantheus Tumor Radioimmunotherapy Introduction
11.3.4 Lantheus Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.3.5 Lantheus Recent Development
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Details
11.4.2 Aurobindo Pharma Business Overview
11.4.3 Aurobindo Pharma Tumor Radioimmunotherapy Introduction
11.4.4 Aurobindo Pharma Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.4.5 Aurobindo Pharma Recent Development
11.5 Mundipharma
11.5.1 Mundipharma Company Details
11.5.2 Mundipharma Business Overview
11.5.3 Mundipharma Tumor Radioimmunotherapy Introduction
11.5.4 Mundipharma Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.5.5 Mundipharma Recent Development
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Details
11.6.2 China Isotope & Radiation Business Overview
11.6.3 China Isotope & Radiation Tumor Radioimmunotherapy Introduction
11.6.4 China Isotope & Radiation Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.6.5 China Isotope & Radiation Recent Development
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Details
11.7.2 Curium Pharmaceuticals Business Overview
11.7.3 Curium Pharmaceuticals Tumor Radioimmunotherapy Introduction
11.7.4 Curium Pharmaceuticals Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.7.5 Curium Pharmaceuticals Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Tumor Radioimmunotherapy Introduction
11.8.4 Gilead Sciences Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.8.5 Gilead Sciences Recent Development
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Details
11.9.2 Clarity Pharmaceuticals Business Overview
11.9.3 Clarity Pharmaceuticals Tumor Radioimmunotherapy Introduction
11.9.4 Clarity Pharmaceuticals Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.9.5 Clarity Pharmaceuticals Recent Development
11.10 Curasight
11.10.1 Curasight Company Details
11.10.2 Curasight Business Overview
11.10.3 Curasight Tumor Radioimmunotherapy Introduction
11.10.4 Curasight Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.10.5 Curasight Recent Development
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Details
11.11.2 Nordic Nanovector Business Overview
11.11.3 Nordic Nanovector Tumor Radioimmunotherapy Introduction
11.11.4 Nordic Nanovector Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.11.5 Nordic Nanovector Recent Development
11.12 Philogen
11.12.1 Philogen Company Details
11.12.2 Philogen Business Overview
11.12.3 Philogen Tumor Radioimmunotherapy Introduction
11.12.4 Philogen Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.12.5 Philogen Recent Development
11.13 RadioMedix
11.13.1 RadioMedix Company Details
11.13.2 RadioMedix Business Overview
11.13.3 RadioMedix Tumor Radioimmunotherapy Introduction
11.13.4 RadioMedix Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.13.5 RadioMedix Recent Development
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Details
11.14.2 Telix Pharmaceuticals Business Overview
11.14.3 Telix Pharmaceuticals Tumor Radioimmunotherapy Introduction
11.14.4 Telix Pharmaceuticals Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.14.5 Telix Pharmaceuticals Recent Development
11.15 Orano Med
11.15.1 Orano Med Company Details
11.15.2 Orano Med Business Overview
11.15.3 Orano Med Tumor Radioimmunotherapy Introduction
11.15.4 Orano Med Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.15.5 Orano Med Recent Development
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Details
11.16.2 Actinium Pharmaceuticals Business Overview
11.16.3 Actinium Pharmaceuticals Tumor Radioimmunotherapy Introduction
11.16.4 Actinium Pharmaceuticals Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.16.5 Actinium Pharmaceuticals Recent Development
11.17 Y-mAbs Therapeutics
11.17.1 Y-mAbs Therapeutics Company Details
11.17.2 Y-mAbs Therapeutics Business Overview
11.17.3 Y-mAbs Therapeutics Tumor Radioimmunotherapy Introduction
11.17.4 Y-mAbs Therapeutics Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.17.5 Y-mAbs Therapeutics Recent Development
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Details
11.18.2 Fusion Pharmaceuticals Business Overview
11.18.3 Fusion Pharmaceuticals Tumor Radioimmunotherapy Introduction
11.18.4 Fusion Pharmaceuticals Revenue in Tumor Radioimmunotherapy Business (2021–2026)
11.18.5 Fusion Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Tumor Radioimmunotherapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Beta-emitting
Table 3. Key Players of Targeted Alpha Therapy
Table 4. Global Tumor Radioimmunotherapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Tumor Radioimmunotherapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Tumor Radioimmunotherapy Market Size by Region (US$ Million), 2021–2026
Table 7. Global Tumor Radioimmunotherapy Market Share by Region (2021–2026)
Table 8. Global Tumor Radioimmunotherapy Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Tumor Radioimmunotherapy Market Share by Region (2027–2032)
Table 10. Tumor Radioimmunotherapy Market Trends
Table 11. Tumor Radioimmunotherapy Market Drivers
Table 12. Tumor Radioimmunotherapy Market Challenges
Table 13. Tumor Radioimmunotherapy Market Restraints
Table 14. Global Tumor Radioimmunotherapy Revenue by Players (US$ Million), 2021–2026
Table 15. Global Tumor Radioimmunotherapy Market Share by Players (2021–2026)
Table 16. Global Top Tumor Radioimmunotherapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on Tumor Radioimmunotherapy Revenue, 2025
Table 17. Ranking of Global Top Tumor Radioimmunotherapy Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Tumor Radioimmunotherapy Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Tumor Radioimmunotherapy, Headquarters and Area Served
Table 20. Global Key Players of Tumor Radioimmunotherapy, Products and Applications
Table 21. Global Key Players of Tumor Radioimmunotherapy, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Tumor Radioimmunotherapy Market Size by Type (US$ Million), 2021–2026
Table 24. Global Tumor Radioimmunotherapy Revenue Market Share by Type (2021–2026)
Table 25. Global Tumor Radioimmunotherapy Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Tumor Radioimmunotherapy Revenue Market Share by Type (2027–2032)
Table 27. Global Tumor Radioimmunotherapy Market Size by Application (US$ Million), 2021–2026
Table 28. Global Tumor Radioimmunotherapy Revenue Market Share by Application (2021–2026)
Table 29. Global Tumor Radioimmunotherapy Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global Tumor Radioimmunotherapy Revenue Market Share by Application (2027–2032)
Table 31. North America Tumor Radioimmunotherapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Tumor Radioimmunotherapy Market Size by Country (US$ Million), 2021–2026
Table 33. North America Tumor Radioimmunotherapy Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Tumor Radioimmunotherapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Tumor Radioimmunotherapy Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Tumor Radioimmunotherapy Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Tumor Radioimmunotherapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Tumor Radioimmunotherapy Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Tumor Radioimmunotherapy Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Tumor Radioimmunotherapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Tumor Radioimmunotherapy Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Tumor Radioimmunotherapy Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Tumor Radioimmunotherapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Tumor Radioimmunotherapy Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Tumor Radioimmunotherapy Market Size by Country (US$ Million), 2027–2032
Table 46. Bayer Company Details
Table 47. Bayer Business Overview
Table 48. Bayer Tumor Radioimmunotherapy Product
Table 49. Bayer Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 50. Bayer Recent Development
Table 51. Novartis Company Details
Table 52. Novartis Business Overview
Table 53. Novartis Tumor Radioimmunotherapy Product
Table 54. Novartis Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 55. Novartis Recent Development
Table 56. Lantheus Company Details
Table 57. Lantheus Business Overview
Table 58. Lantheus Tumor Radioimmunotherapy Product
Table 59. Lantheus Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 60. Lantheus Recent Development
Table 61. Aurobindo Pharma Company Details
Table 62. Aurobindo Pharma Business Overview
Table 63. Aurobindo Pharma Tumor Radioimmunotherapy Product
Table 64. Aurobindo Pharma Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 65. Aurobindo Pharma Recent Development
Table 66. Mundipharma Company Details
Table 67. Mundipharma Business Overview
Table 68. Mundipharma Tumor Radioimmunotherapy Product
Table 69. Mundipharma Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 70. Mundipharma Recent Development
Table 71. China Isotope & Radiation Company Details
Table 72. China Isotope & Radiation Business Overview
Table 73. China Isotope & Radiation Tumor Radioimmunotherapy Product
Table 74. China Isotope & Radiation Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 75. China Isotope & Radiation Recent Development
Table 76. Curium Pharmaceuticals Company Details
Table 77. Curium Pharmaceuticals Business Overview
Table 78. Curium Pharmaceuticals Tumor Radioimmunotherapy Product
Table 79. Curium Pharmaceuticals Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 80. Curium Pharmaceuticals Recent Development
Table 81. Gilead Sciences Company Details
Table 82. Gilead Sciences Business Overview
Table 83. Gilead Sciences Tumor Radioimmunotherapy Product
Table 84. Gilead Sciences Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 85. Gilead Sciences Recent Development
Table 86. Clarity Pharmaceuticals Company Details
Table 87. Clarity Pharmaceuticals Business Overview
Table 88. Clarity Pharmaceuticals Tumor Radioimmunotherapy Product
Table 89. Clarity Pharmaceuticals Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 90. Clarity Pharmaceuticals Recent Development
Table 91. Curasight Company Details
Table 92. Curasight Business Overview
Table 93. Curasight Tumor Radioimmunotherapy Product
Table 94. Curasight Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 95. Curasight Recent Development
Table 96. Nordic Nanovector Company Details
Table 97. Nordic Nanovector Business Overview
Table 98. Nordic Nanovector Tumor Radioimmunotherapy Product
Table 99. Nordic Nanovector Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 100. Nordic Nanovector Recent Development
Table 101. Philogen Company Details
Table 102. Philogen Business Overview
Table 103. Philogen Tumor Radioimmunotherapy Product
Table 104. Philogen Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 105. Philogen Recent Development
Table 106. RadioMedix Company Details
Table 107. RadioMedix Business Overview
Table 108. RadioMedix Tumor Radioimmunotherapy Product
Table 109. RadioMedix Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 110. RadioMedix Recent Development
Table 111. Telix Pharmaceuticals Company Details
Table 112. Telix Pharmaceuticals Business Overview
Table 113. Telix Pharmaceuticals Tumor Radioimmunotherapy Product
Table 114. Telix Pharmaceuticals Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 115. Telix Pharmaceuticals Recent Development
Table 116. Orano Med Company Details
Table 117. Orano Med Business Overview
Table 118. Orano Med Tumor Radioimmunotherapy Product
Table 119. Orano Med Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 120. Orano Med Recent Development
Table 121. Actinium Pharmaceuticals Company Details
Table 122. Actinium Pharmaceuticals Business Overview
Table 123. Actinium Pharmaceuticals Tumor Radioimmunotherapy Product
Table 124. Actinium Pharmaceuticals Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 125. Actinium Pharmaceuticals Recent Development
Table 126. Y-mAbs Therapeutics Company Details
Table 127. Y-mAbs Therapeutics Business Overview
Table 128. Y-mAbs Therapeutics Tumor Radioimmunotherapy Product
Table 129. Y-mAbs Therapeutics Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 130. Y-mAbs Therapeutics Recent Development
Table 131. Fusion Pharmaceuticals Company Details
Table 132. Fusion Pharmaceuticals Business Overview
Table 133. Fusion Pharmaceuticals Tumor Radioimmunotherapy Product
Table 134. Fusion Pharmaceuticals Revenue in Tumor Radioimmunotherapy Business (US$ Million), 2021–2026
Table 135. Fusion Pharmaceuticals Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
Table 139. Authors List of This Report


List of Figures
Figure 1. Tumor Radioimmunotherapy Picture
Figure 2. Global Tumor Radioimmunotherapy Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Tumor Radioimmunotherapy Market Share by Type: 2025 vs 2032
Figure 4. Beta-emitting Features
Figure 5. Targeted Alpha Therapy Features
Figure 6. Global Tumor Radioimmunotherapy Market Size by Application (US$ Million), 2021–2032
Figure 7. Global Tumor Radioimmunotherapy Market Share by Application: 2025 vs 2032
Figure 8. Solid Tumor Case Studies
Figure 9. Non Hodgkin Lymphoma Case Studies
Figure 10. Tumor Radioimmunotherapy Report Years Considered
Figure 11. Global Tumor Radioimmunotherapy Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 12. Global Tumor Radioimmunotherapy Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Tumor Radioimmunotherapy Market Share by Region: 2025 vs 2032
Figure 14. Global Tumor Radioimmunotherapy Market Share by Players in 2025
Figure 15. Global Tumor Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by Tumor Radioimmunotherapy Revenue in 2025
Figure 17. North America Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 18. North America Tumor Radioimmunotherapy Market Share by Country (2021–2032)
Figure 19. United States Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. Canada Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. Europe Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Europe Tumor Radioimmunotherapy Market Share by Country (2021–2032)
Figure 23. Germany Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. France Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. U.K. Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Italy Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Russia Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Ireland Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Asia-Pacific Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Asia-Pacific Tumor Radioimmunotherapy Market Share by Region (2021–2032)
Figure 31. China Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Japan Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. South Korea Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Southeast Asia Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. India Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Australia & New Zealand Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Latin America Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Latin America Tumor Radioimmunotherapy Market Share by Country (2021–2032)
Figure 39. Mexico Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Brazil Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Middle East & Africa Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Middle East & Africa Tumor Radioimmunotherapy Market Share by Country (2021–2032)
Figure 43. Israel Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Saudi Arabia Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. UAE Tumor Radioimmunotherapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Bayer Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 47. Novartis Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 48. Lantheus Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 49. Aurobindo Pharma Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 50. Mundipharma Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 51. China Isotope & Radiation Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 52. Curium Pharmaceuticals Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 53. Gilead Sciences Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 54. Clarity Pharmaceuticals Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 55. Curasight Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 56. Nordic Nanovector Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 57. Philogen Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 58. RadioMedix Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 59. Telix Pharmaceuticals Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 60. Orano Med Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 61. Actinium Pharmaceuticals Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 62. Y-mAbs Therapeutics Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 63. Fusion Pharmaceuticals Revenue Growth Rate in Tumor Radioimmunotherapy Business (2021–2026)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit